Pharmaceuticals

Growth In The Zolgensma Market Is Being Driven By Rising Genetic Disorder Cases Fueling The Growth Of The Due To Increasing Inheritable Mutations

May 6, 2026 by Marketing Posting

The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.

How Is The Market Size Of The Zolgensma Market Expected To Scale Between 2026 And 2030?

Historically, the observed growth was driven by advancements in gene therapy delivery systems, successful clinical outcomes in addressing SMA type 1, prompt identification facilitated by newborn screening, favorable regulatory environments for gene therapies, and the increasing availability of pediatric neuromuscular care.

The projected market expansion over the forecast period is driven by escalating investments in gene therapy development, the widening scope of newborn screening initiatives, a heightened demand for curative therapies for rare diseases, significant progress in viral vector production, and an increased emphasis on the enduring economic advantages in healthcare.

Key developments characterizing the forecast period involve a rising acceptance of single-dose gene therapies, a stronger focus on timely genetic interventions, the expanding application of viral vector technologies, the broadening of curative therapeutic methods, and a greater importance placed on achieving sustained patient survival.

Access Your Free Sample Report For In-Depth Market Analysis:

https://www.thebusinessresearchcompany.com/sample.aspx?id=20373&type=smp

What Primary Drivers Are Shaping The Zolgensma Market?

The zolgensma market is projected to expand due to the growing occurrence of spinal muscular atrophy (SMA). SMA, a genetic condition, causes motor neuron degeneration in the spinal cord, resulting in progressive muscle weakness and atrophy, predominantly in infants and young children, often leading to severe physical disabilities and life-threatening issues. This increase in SMA cases is largely due to advancements in genetic testing and newborn screening, allowing for earlier and more precise diagnoses of previously undetected instances. Zolgensma addresses the root genetic cause of SMA by providing a functional SMN1 gene copy, which helps in producing the crucial survival motor neuron (SMN) protein, vital for motor function and muscle strength, thus enhancing motor skills and survival for affected infants and young children. For example, the Nice organization, a UK-based health guidance provider, reported in August 2025 that spinal muscular atrophy is estimated to affect approximately 1 out of every 14,000 births worldwide, with around 47 babies born with SMA in the UK alone in 2023. Consequently, the rising incidence of spinal muscular atrophy is fueling the expansion of the zolgensma market. The zolgensma market is anticipated to grow with the increasing prevalence of rare diseases. A rare disease is defined as a medical condition impacting a small fraction of the population, frequently presenting with distinct symptoms and difficulties in both diagnosis and treatment. This increase in the occurrence of rare diseases is linked to better diagnostic instruments and heightened public awareness, which enable quicker detection and identification of conditions that might have previously gone undiagnosed. Zolgensma provides treatment for rare conditions such as spinal muscular atrophy by introducing a functional version of the compromised SMN1 gene, thereby allowing for the creation of the SMN protein, essential for motor neuron survival and muscle function. For example, in September 2024, the European Union, an international organization based in the Netherlands, stated that more than 6,000 distinct rare diseases collectively impact up to 36 million people throughout the European Union. Consequently, the rising prevalence of rare diseases is stimulating the expansion of the zolgensma market.

What Are The Key Segment Divisions In The Zolgensma Market Segment Structure?

The zolgensma market covered in this report is segmented –

1) By Indication: Spinal Muscular Atrophy (SMA) Type 1, Spinal Muscular Atrophy (SMA) Type 2, Spinal Muscular Atrophy (SMA) Type 3, Pre-symptomatic Spinal Muscular Atrophy (SMA)

2) By Age Group: Pediatric (Infants And Children), Adults

3) By Distribution Channel: Hospitals, Specialty Clinics, Pharmacies

Which Organizations Are Engaged In The Zolgensma Market?

Major companies operating in the zolgensma market are Novartis AG

Get The Full Zolgensma Market Report:

https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report

Which Region Represents The Largest Share Of The Zolgensma Market?

North America was the largest region in the zolgensma market in 2025. The regions covered in the zolgensma market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Zolgensma Market Report For Competitive Insights:

https://www.thebusinessresearchcompany.com/report/zolgensma-global-market-report

Browse Through More Reports Similar to the Global Zolgensma Market 2026, By The Business Research Company

Zinc Chemicals Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-chemicals-global-market-report

Zinc Oxide Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-oxide-global-market-report

Zinc Market Report 2026

https://www.thebusinessresearchcompany.com/report/zinc-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795